STAT+: Gilead licenses drugs from Arcus in potentially lucrative but risky bet on its cancer business

Gilead will license four Arcus cancer drugs, another potentially lucrative but risky effort to grow its cancer business, which has struggled to gain traction apart from its bespoke CAR-T therapies.

Click to view original post